Base-case values and plausible ranges of input parameters
| Model input | Base-case value | Range | Distribution | Source |
| Outcomes at first 3 months for patients with alteplase | ||||
| mRS 0 | 0.124 | 0–1 | 4 | |
| mRS 1 | 0.230 | |||
| mRS 2 | 0.141 | |||
| mRS 3 | 0.133 | |||
| mRS 4 | 0.133 | |||
| mRS 5 | 0.124 | |||
| mRS 6 | 0.115 | |||
| Outcomes at first 3 months for patients with placebo | ||||
| mRS 0 | 0.107 | 0–1 | Dirichlet | 4 |
| mRS 1 | 0.188 | |||
| mRS 2 | 0.134 | |||
| mRS 3 | 0.143 | |||
| mRS 4 | 0.214 | |||
| mRS 5 | 0.125 | |||
| mRS 6 | 0.089 | |||
| Probability of ICH with alteplase | 0.062 | 0.030–0.122 | Beta, SD 0.023 | 4 |
| Probability of ICH with placebo | 0.009 | 0.002–0.049 | Beta, SD 0.012 | 4 |
| Annual probability of recurrent stroke in China | 0.118 | 0.112–0.124 | Beta, SD 0.003 | 5 |
| Death after recurrent stroke in China | 0.210 | 0.189–0.232 | Beta, SD 0.011 | 5 |
| Annual probability of recurrent stroke in the US | 0.050 | 0.040–0.060 | Beta, SD 0.005 | 6 |
| Death after recurrent stroke in the US | 0.190 | 0.100–0.300 | Beta, SD 0.05 | 7 |
| Death hazard ratios | ||||
| mRS 0 | 1 | 1–1.2 | Lognormal, SD 0.050 | 14 |
| mRS 1 | 1 | 1–1.2 | Lognormal, SD 0.050 | |
| mRS 2 | 1.11 | 0.89–1.3 | Lognormal, SD 0.103 | |
| mRS 3 | 1.27 | 1.02–1.52 | Lognormal, SD 0.125 | |
| mRS 4 | 1.71 | 1.37–2.05 | Lognormal, SD 0.170 | |
| mRS 5 | 2.37 | 1.90–2.84 | Lognormal, SD 0.235 | |
| Cost in China (¥) | ||||
| MRI | 600 | ±25% | Gamma, SD 75 | 16 |
| Imaging processing with RAPID software | 1000 | ±25% | Gamma, SD 125 | Institutional database |
| Additional cost of r-tPA treatment | 13 886 | 10 751–16 194 | Gamma, SD 1361 | 5 |
| Acute stroke (mRS 0–1) | 12 214 | 7055–15 379 | Gamma, SD 2081 | 5 |
| Acute stroke (mRS 2–5) | 16 149 | 8875–21 177 | Gamma, SD 3076 | 5 |
| Acute stroke (death) | 13 840 | 6503–18 293 | Gamma, SD 2948 | 5 |
| ICH | 2949 | 641–6155 | Gamma, SD 1379 | 5 |
| Annual posthospitalization (mRS 0–1) | 8684 | 2600–11 077 | Gamma, SD 2119 | 5 |
| Annual posthospitalization (mRS 2–5) | 13 213 | 3323–16 616 | Gamma, SD 3323 | 5 |
| Recurrent stroke | 18 000 | ±25% | Gamma, SD 2250 | Institutional database |
| Cost in the US (US$) | ||||
| MRI | 816 | ±25% | Gamma, SD 102 | 17 |
| Imaging processing with RAPID software | 12 000 | ±25% | Gamma, SD 1500 | 19 |
| Additional cost of alteplase treatment | 8619 | 4309–12 928 | Gamma, SD 2155 | 8 |
| Acute stroke (mRS 0–3) | 9268 | 4633–13 901 | Gamma, SD 2317 | 18 |
| Acute stroke (mRS 4–5) | 14 115 | 7057–21 171 | Gamma, SD 3529 | 18 |
| Acute stroke (death) | 16 457 | 8228–24 685 | Gamma, SD 4114 | 18 |
| ICH | 3399 | 2719–4079 | Gamma, SD 340 | 18 |
| Annual posthospitalization (mRS 0–3) | 8157 | 4078–12 235 | Gamma, SD 2039 | 18 |
| Annual posthospitalization (mRS 4–5) | 22 139 | 11 070–33 209 | Gamma, SD 5535 | 18 |
| Recurrent stroke | 25 143 | 12 572–37 715 | Gamma, SD 6286 | 8 |
| Utility | ||||
| mRS 0 | 0.80 | 0.64–1 | Beta, SD 0.090 | 14 |
| mRS 1 | 0.80 | 0.64–1 | Beta, SD 0.090 | |
| mRS 2 | 0.65 | 0.52–0.78 | Beta, SD 0.065 | |
| mRS 3 | 0.50 | 0.4–0.6 | Beta, SD 0.050 | |
| mRS 4 | 0.35 | 0.28–0.42 | Beta, SD 0.035 | |
| mRS 5 | 0.20 | 0.16–0.24 | Beta, SD 0.020 | |
| Death | 0.00 | NA | NA | NA |
| Disutility of ICH | 0.38 | 0.30–0.46 | Normal, SD 0.040 | 22 |
| Discount rate | 0.03 | 0–0.08 | Beta, SD 0.020 | 23 |
ICH, intracranial hemorrhage; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NA, not available; r-tPA, recombinant tissue-type plasminogen activator; SD, standard deviation; US, United States.